EHA 2025: Biomarkers as a Guide in Lymphoma Treatment

In this MEDtalk, Professor Sirpa Leppä from University of Helsinki and Helsinki University Hospital shares key insights from her presentation at EHA 2025 on biomarker-guided treatment strategies in lymphoma. Drawing on data from the Nordic Lymphoma Group’s BIO-CHIC-trial and other studies, she discusses how biological risk factors – especially circulating tumor DNA (ctDNA) burden, can help identify high-risk subgroups and predict response to therapy.